With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 23 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.
Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development.
Eisai Europe Ltd
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. Our passion and dedication to patient care is the driving force behind our efforts to discover and develop, innovative medicines in areas where a high unmet medical need remains including oncology.
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.
Novartis is reimagining medicine to improve people’s lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines. About 109,000 people of more than 145 nationalities work at Novartis.
MSD Sharp & Dohme GmbH
For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals.
Agendia is a leading precision oncology company that develops genomic tests to support physicians faced with complex treatment decisions. MammaPrint®, the 70-gene signature is an FDA-cleared breast cancer recurrence assay, backed by peer-reviewed, prospective data and included in many guidelines. BluePrint®, the 80-gene molecular subtyping assay looks beyond the cell surface to identify Luminal-type, Basal-type and HER2-type breast cancer.
Exact Sciences is a leading provider of cancer screening and diagnostic tests. From earlier detection to treatment guidance, we are helping people get the answers they need to make more informed decisions. Building on the success of the Oncotype DX® and Cologuard® tests, the company is investing in its pipeline across the cancer continuum.
Gilead, Creating Possible for People with Cancer. At Gilead and Kite, we focus on delivering therapies for patients with some of the most difficult-to-treat cancers. The medicines in our pipeline are being developed to treat cancer by harnessing the power of cell therapy, targeting immune evasion pathways and leveraging first-in-class antibody drug conjugate technology.
Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in Breast Cancer. Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers.
Pierre Fabre is a French pharmaceutical and dermo-cosmetic company. 35-year experience in innovation, development, manufacturing and commercialization has brought Pierre Fabre international recognition in oncology. Today, oncology is one of its top R&D and commercial priorities, focusing on targeted therapies, biotherapies and immuno-oncology. Its therapeutic areas cover high unmet medical needs, including colorectal, breast, lung cancers and melanoma.
Roche is a pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, hematology, and beyond. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases.
We are building on a rich legacy in oncology with a rejuvenated pipeline and a renewed commitment to bring novel treatment options to patients with unmet medical needs. Today, Sanofi Genzyme has a portfolio of medicines indicated across a variety of cancers, including skin, prostate, lung, colon, breast and blood.